Verastem Oncology - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi VSTM

The immediate driver for Verastem, Inc. (VSTM) will be the request for accelerated FDA approval of its ovarian cancer therapy. EBITDA on this GURU.Markets platform chart reflects cash flow dynamics, where 0.00 determines this parameter level. Growth is based on alliances with biolabs and patent acquisitions, while a future monopoly on unique drugs will ensure ultra-high pricing power.

Verastem Inc - Bathi operasional EBITDA VSTM (periode 23.11.2025 - 10.11.2026)

Verastem (VSTM) - rincian metrik lan laporan keuangan

- nilai pasar lan prakiraan target analis:

Rega bursa Verastem Corp|VSTM - Target konsensus

- rincian nilai pasar emiten:

Nilai pasar Verastem|VSTM - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- informasi kapitalisasi buku:

Rega Buku Saham Verastem|VSTM - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku verastem.com|VSTM - Aset Agregat Perusahaan

- indikator total utang lan likuiditas perusahaan:

Rasio Kabeh Utang marang Dana Pribadi Verastem, Inc.|VSTM - Utang jangka dawa marang modal|Tanggungan utang jangka cendhak marang ekuitas Verastem Oncology|VSTM - Gunggung utang perusahaan|Utang-utang marang nilai buku Verastem|VSTM - Kewajiban jangka dawa perusahaan|Gedhene kewajiban jangka cendhak Verastem|Likuiditas darurat verastem.com

- rincian asil keuangan lan kelipatan valuasi:

VSTM - Bathi resik|Prakiraan bathi resik Verastem, Inc.|VSTM - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi verastem.com|VSTM - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Verastem|VSTM - Bathi operasional EBITDA|Bathi saben saham sajroning taun lumaku Verastem|VSTM - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan verastem.com|VSTM - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Verastem, Inc.

Ringkesan analitik perusahaan:Verastem, Inc.

This indicator measures net cash flow from operating activities before interest and taxes, eliminating the time lag associated with quarterly reporting. For Verastem, Inc. (VSTM), this metric reflects the stability of development funding amid geopolitical disruptions in clinical trials. By analyzing the EBITDA_Co trend, an investor can discern the actual speed of liquidity generation. This enables an assessment of the company's ability to maintain biomaterial supply chains. Steady growth in this indicator confirms the long-term fundamental viability of the business.

Analisis pesaing Verastem, Inc.